December 2, 2015

The promise and pitfalls of long-acting injectable agents for HIV prevention

Key Points

Key points are not available for this paper at this time.

Abstract

Long-acting injectable formulations, if safe and well tolerated, may improve pharmacokinetic coverage of exposures to HIV infection. Complexities around safety, tolerability, and starting/stopping protocols require careful consideration.

Demander à l'IA

Bookmark

Demander à l'IA

Bookmark

Cite This Study

Landovitz et al. (Wed,) studied this question.

synapsesocial.com/papers/69d7db05ec32c73b01ae30ec https://doi.org/https://doi.org/10.1097/coh.0000000000000219

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database2008 · 53 citations
2TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-12009 · 294 citations
3Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men2010 · 5,142 citations
4Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor2013 · 113 citations
5Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials2015 · 19 citations